Business Context and Reporting Period
Company: Gain Therapeutics, Inc. (GANX)
Filing Type: Form 8-K (Current Report)
Date of Report: October 6, 2025
Event: Presentation of preliminary data from the ongoing Phase 1b clinical study of GT-02287 for Parkinson's disease (PD) at the International Congress of Parkinson's Disease and Movement Disorders.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding clinical trial updates and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Findings
- Safety Profile: After 90 days of dosing, GT-02287 was safe and generally well tolerated with no treatment-emergent serious adverse events. A transient increase in alkaline phosphatase and other liver enzymes was observed in some participants but normalized despite ongoing dosing.
- Study Population: 21 participants total (2 treatment-naïve, 2 on deep brain stimulation, 18 on levodopa/dopamine agonists).
- Efficacy Signals: Mean MDS-UPDRS baseline scores were 5.8 (Part I), 7.4 (Part II), and 24.7 (Part III). Several participants showed improvement in Parts II and III after 90 days, while Part I remained unchanged. Improvements were not observed at Day 30, suggesting a potential disease-slowing effect.
- Pharmacokinetics: Plasma PK profiles were consistent across 14 sampled participants, within the projected therapeutic range, and comparable to healthy volunteer exposures.
- Regulatory Status: The data monitoring committee recommended study continuation. Australian health authorities approved a study extension allowing treatment for up to 12 months.
Outlook and Management Commentary
Management indicates that the observed mean improvement in UPDRS Parts II and III supports the proposed mechanism of action and preclinical models, justifying continued development of GT-02287. The approval of the study extension in Australia facilitates longer-term data collection.
Investor Verification Checklist
- Verify the full statistical analysis of the UPDRS Part II and III improvements beyond the "several participants" mentioned.
- Confirm the specific timeline and criteria for the Australian Phase 1b study extension.
- Monitor upcoming financial filings (10-Q/10-K) for cash burn rates and funding status, as this 8-K contains no financial data.
- Review the complete safety data regarding the transient liver enzyme elevations to assess long-term tolerability.